Related Experiment Video
Updated: Jan 2, 2026
09:11
Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release
Published on: February 13, 2016
10.2K
Electrostatically Driven Guanidinium Interaction Domains that Control Hydrogel-Mediated Protein Delivery In Vivo
Stephen E Miller1, Yuji Yamada1, Nimit Patel2
1Chemical Biology Laboratory and Cancer and Inflammation Program, National Cancer Institute, Frederick, Maryland 21702, United States.
ACS Central Science
|December 7, 2019
Summary
A novel protein delivery platform uses designed interaction domains and a hydrogel to prevent protein denaturation, enabling tunable, long-term drug release from a single subcutaneous injection.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Protein Engineering
Background:
- Parenteral administration of protein biologics is limited by frequent dosing requirements.
- Protein adsorption to drug-delivery materials can cause denaturation and reduced efficacy.
Purpose of the Study:
- To develop a new protein delivery platform for sustained, controlled release.
- To overcome protein denaturation issues associated with current drug delivery materials.
Main Methods:
- Utilized designed interaction domains (IDs) on proteins and a negatively charged self-assembled fibrillar hydrogel.
- Employed complementary electrostatic interactions to modulate protein-material binding and release kinetics.
- Conducted molecular dynamics simulations to understand release mechanisms and optimize binding interactions.
Main Results:
- The platform limits direct contact between proteins and the material matrix, enhancing protein stability.
- Protein release kinetics are tunable by modifying interaction domains, achieving diverse in vitro release rates.
- Demonstrated long-term in vivo protein delivery control via subcutaneous administration.
Conclusions:
- The developed platform offers a versatile solution for sustained protein drug delivery.
- This approach enhances protein stability and allows for precise control over release profiles.
- The technology has potential for improved therapeutic outcomes with reduced administration frequency.
